Company Filing History:

10 out of 723

Zymogenetics, Inc.

patents

4. 1 out of 832,680

Other

patents

where one patent can have more than one assignee

Years Active: 1988-2013

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8603777 - Expression of factor VII and IX activities in mammalian cells (2013-12-10),

2. 6168789 - Modified factor VII (2001-01-02),

3. 6039944 - Modified Factor VII (2000-03-21),

4. 5861374 - Modified Factor VII (1999-01-19),

5. 5833982 - Modified factor VII (1998-11-10),

6. 5824639 - Modified factor VII anticoagulant proteins (1998-10-20),

7. 5817788 - Modified factor VII (1998-10-06),

8. 5788965 - Modified factor VII (1998-08-04),

9. 5516650 - Production of activated protein C (1996-05-14),

10. 5288629 - DNA sequence encoding Factor VII with an amino acid substitution at (1994-02-22),

11. 4959318 - Expression of protein C (1990-09-25),

12. 4784950 - Expression of factor VII activity in mammalian cells (1988-11-15),

Title: Innovations and Contributions of Kathleen L Berkner

Introduction

Kathleen L Berkner is a prominent inventor based in Seattle, WA (US). She has made significant contributions to the field of blood coagulation through her innovative research and development. With a total of 12 patents, her work has had a profound impact on medical science and treatment options for coagulation-related disorders.

Latest Patents

Among her latest patents, Berkner has developed methods for the expression of factor VII and IX activities in mammalian cells. These methods involve producing proteins that have biological activity for blood coagulation mediated by Factor VIIa or Factor IX. The proteins are generated by mammalian host cells that have been stably transfected with a DNA construct containing a nucleotide sequence coding for either Factor VII or Factor IX. This sequence includes a calcium binding domain and a catalytic domain for serine protease activity. The resulting proteins exhibit biological activity similar to that of Factor VIIa or Factor IX. Additionally, she has modified Factor VII to create a compound that effectively interrupts the blood coagulation cascade. This modification renders Factor VIIa substantially unable to activate plasma Factors X or IX, leading to pharmaceutical compositions that treat various coagulation-related disorders.

Career Highlights

Berkner has worked with notable companies such as Zymogenetics, Inc. and Novo Nordisk A/S. Her career has been marked by a commitment to advancing medical treatments and improving patient outcomes through her innovative inventions.

Collaborations

Throughout her career, Berkner has collaborated with esteemed colleagues, including Lars Christian Petersen and Charles E Hart. These partnerships have further enhanced her research and development efforts in the field of blood coagulation.

Conclusion

Kathleen L Berkner's contributions to the field of blood coagulation through her patents and collaborations have established her as a leading inventor. Her innovative methods and modifications have the potential to significantly improve treatment options for patients with coagulation disorders.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.